Posaconazole for the treatment of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. (25th February 2019)

• Record Type: Journal Article
• Authors: Periselneris, J; Nwankwo, L; Schelenz, S; Shah, A; Armstrong-James, D
• Is Part Of: Journal of antimicrobial chemotherapy. Volume 74:Number 6(2019)
• Page Start: 1701
• Page End: 1703
• Publication Date: 2019-02-25
• Subjects: Anti-infective agents -- Periodicals; Chemotherapy -- Periodicals; 615.58
• DOI: 10.1093/jac/dkz075
• Languages: English
• ISSNs: 0305-7453

Abstract

Abstract: Objectives: Allergic bronchopulmonary aspergillosis (ABPA) can accelerate lung function decline in patients with cystic fibrosis (CF). Antifungal medication can be used in addition to systemic corticosteroid treatment. Patients and methods: We evaluated Aspergillus -specific IgE and the use of therapeutic drug monitoring of triazoles in a retrospective analysis of 32 patients. Results: There was a significant reduction in Aspergillus IgE with posaconazole but not with other triazoles ( P = 0.026). Aspergillus IgE levels were inversely correlated with the therapeutic drug level of posaconazole. Conclusions: These data suggest that posaconazole is better than comparator azoles at decreasing serological response to Aspergillus and that this response was better with therapeutic levels of posaconazole.